DUBLIN--(BUSINESS WIRE)--The "Nanomedicine Market by Modality - Global Opportunity Analysis and Industry Forecast, 2017-2023" report has been added to ResearchAndMarkets.com's offering.
The global nanomedicine market accounted for $111,912 million in 2016, and is anticipated to reach $261,063 million by 2023, registering a CAGR of 12.6% from 2017 to 2023.
Nanomedicine is a branch of medicine that uses tools and knowledge of nanotechnology for prevention and treatment of different diseases. Nanomedicines are multifunctional drugs with programmable properties that find applications in monitoring, construction, repair, and control of biological systems at the molecular level using nanodevices and nanoparticles. These nanomedicines have the potential to revolutionize the current scenario of detection of disease, its treatment, and diagnosis methods.
The global nanomedicine market is driven by emerging innovative technologies for drug delivery, advantages of nanomedicine in various healthcare applications, rise in government support and funding, and growth in need for safe and cost-effective therapies. However, long approval process and risks associated with nanomedicine (environmental impacts) restrain the market growth. In addition, increase in out-licensing of nanodrugs and growth of healthcare facilities in emerging economies are anticipated to provide numerous opportunities for the market growth.
The global nanomedicine market is segmented based on modality, application, indication, and region. Based on application, it is classified into drug delivery, diagnostic imaging, vaccines, regenerative medicine, implants, and others. Based on indication, it is categoried into oncological diseases, neurological diseases, urological diseases, infectious diseases, ophthalmological diseases, orthopaedic disorders, immunological diseases, cardiovascular diseases, and others. On the basis of modality, it is bifurcated into treatments and diagnostics.
- Abbott Laboratories
- CombiMatrix Corporation
- General electric Company
- Sigma-Tau Pharmaceuticals, Inc.
- Johnson & Johnson
- Mallinckrodt plc.
- Merck & Company, Inc.
- Nanosphere, Inc.
- Pfizer, Inc.
- Teva Pharmaceutical Industries Ltd.
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Executive Summary
Chapter 3 Market Overview
Chapter 4 Nanomedicine Market, By Application
Chapter 5 Nanomedicine Market, By Indication
Chapter 6 Nanomedicine Market, By Modality
Chapter 7 Nanomedicine Market, By Region
Chapter 8 Company Profiles
For more information about this report visit https://www.researchandmarkets.com/research/kj42bk/global?w=4